文献

J-GLOBAL ID：202002227831983439   整理番号：20A2059679

COVID-19に対する熱安定性mRNAワクチン【JST・京大機械翻訳】

A Thermostable mRNA Vaccine against COVID-19

著者 (32件)： Zhang Na-Na (State Key Laboratory of Pathogen and Biosecurity, Beijing Institute of Microbiology and Epidemiology, Academy of Military Medical Sciences, Beijing 100071, China) ,  Zhang Na-Na (School of Medicine, Tsinghua University, Beijing 100084, China) ,  Li Xiao-Feng (State Key Laboratory of Pathogen and Biosecurity, Beijing Institute of Microbiology and Epidemiology, Academy of Military Medical Sciences, Beijing 100071, China) ,  Deng Yong-Qiang (State Key Laboratory of Pathogen and Biosecurity, Beijing Institute of Microbiology and Epidemiology, Academy of Military Medical Sciences, Beijing 100071, China) ,  Zhao Hui (State Key Laboratory of Pathogen and Biosecurity, Beijing Institute of Microbiology and Epidemiology, Academy of Military Medical Sciences, Beijing 100071, China) ,  Huang Yi-Jiao (State Key Laboratory of Pathogen and Biosecurity, Beijing Institute of Microbiology and Epidemiology, Academy of Military Medical Sciences, Beijing 100071, China) ,  Yang Guan (State Key Laboratory of Proteomics, Beijing Proteome Research Center, National Center for Protein Sciences (Beijing), Beijing Institute of Lifeomics, Beijing 102206, China) ,  Huang Wei-Jin (Division of HIV/AIDS and Sex-Transmitted Virus Vaccines, Institute for Biological Product Control, National Institutes for Food and Drug Control (NIFDC), Beijing 102629, China) ,  Gao Peng (Suzhou Abogen Biosciences Co., Ltd., Suzhou 215123, China) ,  Zhou Chao (State Key Laboratory of Pathogen and Biosecurity, Beijing Institute of Microbiology and Epidemiology, Academy of Military Medical Sciences, Beijing 100071, China) ,  Zhang Rong-Rong (State Key Laboratory of Pathogen and Biosecurity, Beijing Institute of Microbiology and Epidemiology, Academy of Military Medical Sciences, Beijing 100071, China) ,  Guo Yan (State Key Laboratory of Pathogen and Biosecurity, Beijing Institute of Microbiology and Epidemiology, Academy of Military Medical Sciences, Beijing 100071, China) ,  Sun Shi-Hui (State Key Laboratory of Pathogen and Biosecurity, Beijing Institute of Microbiology and Epidemiology, Academy of Military Medical Sciences, Beijing 100071, China) ,  Fan Hang (State Key Laboratory of Pathogen and Biosecurity, Beijing Institute of Microbiology and Epidemiology, Academy of Military Medical Sciences, Beijing 100071, China) ,  Zu Shu-Long (State Key Laboratory of Pathogen and Biosecurity, Beijing Institute of Microbiology and Epidemiology, Academy of Military Medical Sciences, Beijing 100071, China) ,  Chen Qi (State Key Laboratory of Pathogen and Biosecurity, Beijing Institute of Microbiology and Epidemiology, Academy of Military Medical Sciences, Beijing 100071, China) ,  He Qi (State Key Laboratory of Proteomics, Beijing Proteome Research Center, National Center for Protein Sciences (Beijing), Beijing Institute of Lifeomics, Beijing 102206, China) ,  Cao Tian-Shu (State Key Laboratory of Pathogen and Biosecurity, Beijing Institute of Microbiology and Epidemiology, Academy of Military Medical Sciences, Beijing 100071, China) ,  Huang Xing-Yao (State Key Laboratory of Pathogen and Biosecurity, Beijing Institute of Microbiology and Epidemiology, Academy of Military Medical Sciences, Beijing 100071, China) ,  Qiu Hong-Ying (State Key Laboratory of Pathogen and Biosecurity, Beijing Institute of Microbiology and Epidemiology, Academy of Military Medical Sciences, Beijing 100071, China) ,  Nie Jian-Hui (Division of HIV/AIDS and Sex-Transmitted Virus Vaccines, Institute for Biological Product Control, National Institutes for Food and Drug Control (NIFDC), Beijing 102629, China) ,  Jiang Yuhang (Suzhou Abogen Biosciences Co., Ltd., Suzhou 215123, China) ,  Yan Hua-Yuan (Suzhou Abogen Biosciences Co., Ltd., Suzhou 215123, China) ,  Ye Qing (State Key Laboratory of Pathogen and Biosecurity, Beijing Institute of Microbiology and Epidemiology, Academy of Military Medical Sciences, Beijing 100071, China) ,  Zhong Xia (Suzhou Abogen Biosciences Co., Ltd., Suzhou 215123, China) ,  Xue Xia-Lin (Suzhou Abogen Biosciences Co., Ltd., Suzhou 215123, China) ,  Zha Zhen-Yu (Suzhou Abogen Biosciences Co., Ltd., Suzhou 215123, China) ,  Zhou Dongsheng (State Key Laboratory of Pathogen and Biosecurity, Beijing Institute of Microbiology and Epidemiology, Academy of Military Medical Sciences, Beijing 100071, China) ,  Yang Xiao (State Key Laboratory of Proteomics, Beijing Proteome Research Center, National Center for Protein Sciences (Beijing), Beijing Institute of Lifeomics, Beijing 102206, China) ,  Wang You-Chun (Division of HIV/AIDS and Sex-Transmitted Virus Vaccines, Institute for Biological Product Control, National Institutes for Food and Drug Control (NIFDC), Beijing 102629, China) ,  Ying Bo (Suzhou Abogen Biosciences Co., Ltd., Suzhou 215123, China) ,  Qin Cheng-Feng (State Key Laboratory of Pathogen and Biosecurity, Beijing Institute of Microbiology and Epidemiology, Academy of Military Medical Sciences, Beijing 100071, China)
資料名： Cell (Cambridge, Mass.)  (Cell (Cambridge, Mass.))
巻： 182  号： 5  ページ： 1271-1283.e16  発行年： 2020年 
JST資料番号： A0707B  ISSN： 0092-8674  資料種別： 逐次刊行物 (A)
記事区分： 原著論文  発行国： アメリカ合衆国 (USA)  言語： 英語 (EN)

抄録/ポイント： 進行中のSARS-CoV-2パンデミックのため,コロナウイルス病2019(COVID-19)に対するワクチンの緊急の必要性がある。すべてのアプローチの中で,メッセンジャーRNA(mRNA)に基づくワクチンは,この課題に迅速に応答する迅速で多目的なプラットフォームとして出現している。ここでは,ワクチン候補(ARCoVと呼ぶ)としてSARS-CoV-2の受容体結合ドメイン(RBD)をコードする脂質ナノ粒子カプセル化mRNA(mRNA-LNP)を開発した。ARCoV mRNA-LNPの筋肉内免疫は,マウスおよび非ヒト霊長類におけるTh1バイアス細胞反応と同様に,SARS-CoV-2に対する頑健な中和抗体を誘導した。マウスにおけるARCoV免疫の2つの用量は,SARS-CoV-2マウス適応株のチャレンジに対して完全な保護を与えた。さらに,ARCoVは液体製剤として製造され,少なくとも1週間室温で貯蔵できる。ARCoVは現在,第1相臨床試験で評価されている。Copyright 2020 Elsevier B.V., Amsterdam. All rights reserved. Translated from English into Japanese by JST.【JST・京大機械翻訳】

シソーラス用語： *mRNA ,  液状製剤 ,  受容体 ,  ヒト ,  *ワクチン ,  霊長類 ,  臨床試験 ,  結合部位 ,  バイアス ,  単相 ,  中和抗体 ,  Th1細胞
準シソーラス用語： コロナウイルス ,  SARSウイルス ,  重症急性呼吸器症候群 , 【Automatic Indexing@JST】

著者キーワード (7件)： SARS-CoV-2 ,  COVID-19 ,  mRNAワクチン ,  脂質ナノ粒子 ,  マウス適応株 ,  非ヒト霊長類 ,  保護

分類 (2件)： 生物学的機能  (EB03040U) ,  免疫療法薬・血液製剤の基礎研究  (GW22010D)

タイトルに関連する用語 (3件)： COVID-19 ,  熱安定性 ,  mRNAワクチン